3,5- bis(2,4- difluorobenzylidene)- 4- piperidone

11/01/2011 - "Taken together, these data suggest that DiFiD is a novel potent therapeutic agent that can target different aspects of the Notch signaling pathway to inhibit both tumor growth and angiogenesis."
01/01/2023 - "A-DiFiD targets c-Jun, a clinical HNSCC driver, with potent anti-tumor effects."
01/01/2023 - "Moreover, DiFiD mediated suppression of DCLK1 led to G2/M arrest and apoptosis and significantly suppressed tumor growth of HNSCC xenografts and ASCC patient derived xenografts, supporting that DCLK1 is critical for SCC growth."
11/01/2011 - "Intraperitoneal administration of DiFiD significantly suppressed growth of pancreatic cancer tumor xenografts. "
11/01/2011 - "In this study, we developed a novel compound 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and determined that it inhibits cancer cell growth and its effects on Notch signaling. "

01/01/2023 - "Of the small molecules tested, A-DiFiD was the most potent in HNSCC lines, while demonstrating low half-maximal drug inhibitory concentration (IC50) in non-malignant Het-1A cells. "
01/01/2023 - "A-DiFiD-treated HNSCC cells were assessed for cytotoxicity, colony formation, invasion, migration, and adhesion. "
01/01/2023 - "A-DiFiD targets c-Jun, a clinical HNSCC driver, with potent anti-tumor effects."
01/01/2023 - "Moreover, DiFiD mediated suppression of DCLK1 led to G2/M arrest and apoptosis and significantly suppressed tumor growth of HNSCC xenografts and ASCC patient derived xenografts, supporting that DCLK1 is critical for SCC growth."

11/01/2011 - "3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis."
11/01/2011 - "Intraperitoneal administration of DiFiD significantly suppressed growth of pancreatic cancer tumor xenografts. "
11/01/2011 - "In vitro, DiFiD inhibited the proliferation of various human and mouse pancreatic cancer cells while increasing activated caspase-3. "